WO2003017932A3 - Compositions and methods for targeting cerebral circulation and treatment of headache - Google Patents

Compositions and methods for targeting cerebral circulation and treatment of headache Download PDF

Info

Publication number
WO2003017932A3
WO2003017932A3 PCT/US2002/026613 US0226613W WO03017932A3 WO 2003017932 A3 WO2003017932 A3 WO 2003017932A3 US 0226613 W US0226613 W US 0226613W WO 03017932 A3 WO03017932 A3 WO 03017932A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
headache
compositions
treatment
cerebral circulation
Prior art date
Application number
PCT/US2002/026613
Other languages
French (fr)
Other versions
WO2003017932A2 (en
WO2003017932B1 (en
Inventor
Bruce Frome
Original Assignee
Epitome Pharmaceuticals Ltd
Bruce Frome
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitome Pharmaceuticals Ltd, Bruce Frome filed Critical Epitome Pharmaceuticals Ltd
Priority to EP02753504A priority Critical patent/EP1418918A4/en
Priority to US10/483,509 priority patent/US7981901B2/en
Priority to AU2002313785A priority patent/AU2002313785A1/en
Publication of WO2003017932A2 publication Critical patent/WO2003017932A2/en
Publication of WO2003017932A3 publication Critical patent/WO2003017932A3/en
Publication of WO2003017932B1 publication Critical patent/WO2003017932B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Abstract

Methods and compositions for targeting cerebral circulation and treatment of headache include formulations comprising a pharmacologically active substance in a transdermal formulation, which is topically applied to an area of skin superficial to a carotid artery, a temporal artery, a vertebral artery, or to a tender spot associated with a headache. Particularly preferred formulations include a xanthine derivative (e.g., theophylline, caffeine, aminophylline), and may further comprise ketoprofen. Contemplated methods further include methods of advertising use of contemplated compositions.
PCT/US2002/026613 2001-08-23 2002-08-20 Compositions and methods for targeting cerebral circulation and treatment of headache WO2003017932A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02753504A EP1418918A4 (en) 2001-08-23 2002-08-20 Compositions and methods for targeting cerebral circulation and treatment of headache
US10/483,509 US7981901B2 (en) 2001-08-23 2002-08-20 Compositions and methods for targeting cerebral circulation and treatment of headache
AU2002313785A AU2002313785A1 (en) 2001-08-23 2002-08-20 Compositions and methods for targeting cerebral circulation and treatment of headache

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2001/026459 WO2003018023A1 (en) 2001-08-23 2001-08-23 Compositions and methods for targeting cerebral circulation and treatment of headache
USPCT/US01/26459 2001-08-23

Publications (3)

Publication Number Publication Date
WO2003017932A2 WO2003017932A2 (en) 2003-03-06
WO2003017932A3 true WO2003017932A3 (en) 2003-07-10
WO2003017932B1 WO2003017932B1 (en) 2003-09-12

Family

ID=21742800

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2001/026459 WO2003018023A1 (en) 2001-08-23 2001-08-23 Compositions and methods for targeting cerebral circulation and treatment of headache
PCT/US2002/026613 WO2003017932A2 (en) 2001-08-23 2002-08-20 Compositions and methods for targeting cerebral circulation and treatment of headache

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2001/026459 WO2003018023A1 (en) 2001-08-23 2001-08-23 Compositions and methods for targeting cerebral circulation and treatment of headache

Country Status (3)

Country Link
EP (1) EP1418918A4 (en)
AU (1) AU2002313785A1 (en)
WO (2) WO2003018023A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250529A (en) * 1990-02-08 1993-10-05 Kos Pharmaceuticals, Inc. Method alleviating migraine headache with mast cell degranulation blocking agents
US5552406A (en) * 1994-06-17 1996-09-03 The Mclean Hospital Corporation Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
US5885597A (en) * 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777174A (en) * 1982-07-22 1988-10-11 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4777147A (en) 1987-01-28 1988-10-11 Texas Instruments Incorporated Forming a split-level CMOS device
HRP921157A2 (en) * 1991-12-20 1994-10-31 Lohmann Therapie Syst Lts Transdermal system of applying acetilsalicilyc acid in antithrombosys therapy
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE10025644A1 (en) * 2000-05-24 2001-12-06 Lohmann Therapie Syst Lts Narrow band-shaped transdermal therapeutic system for the application of active substances directly over the arterial or venous vascular system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250529A (en) * 1990-02-08 1993-10-05 Kos Pharmaceuticals, Inc. Method alleviating migraine headache with mast cell degranulation blocking agents
US5552406A (en) * 1994-06-17 1996-09-03 The Mclean Hospital Corporation Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
US5885597A (en) * 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1418918A4 *

Also Published As

Publication number Publication date
WO2003017932A2 (en) 2003-03-06
EP1418918A2 (en) 2004-05-19
WO2003017932B1 (en) 2003-09-12
AU2002313785A1 (en) 2003-03-10
EP1418918A4 (en) 2006-11-29
WO2003018023A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
Saenz de Tejada et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil
NO20053817L (en) Preparations and Methods for Antiviral Combination Therapy.
BR9712610A (en) Pharmaceutical and liquid compositions, use of acyclovir or a pharmaceutically acceptable derivative thereof, process for preparing a composition, and topical application.
WO2002049593A3 (en) Use of dna repair enzymes as mmp-1 inhibitors
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
TNSN05265A1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
NZ603686A (en) Topical formulation for a jak inhibitor
WO2005056547A3 (en) Quinoxalines useful as inhibitors of protein kinases
WO2005039485A3 (en) Gsk-3 inhibitors and uses thereof
PT957900E (en) COMPOSITIONS AND METHODS FOR TOPIC APPLICATION OF THERAPEUTIC AGENTS
DK1267932T3 (en) Anti-infectious combinations of active substances and their use for topical treatment of fungal diseases of the toe and fingernails
CA2404810A1 (en) Topical composition having undifferentiated plant seed cells and method for using same
AUPR048600A0 (en) Pharmaceutical vehicle
PL2004653T3 (en) 3-substituted n-(aryl- or heteroaryl)-pyrazo[1,5-a]pyrimidines as kinase inhibitors
HK1045986A1 (en) Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders.
WO2001038303A3 (en) Vitamin d analogues
HUP0001632A2 (en) Pharmaceutical compositions comprising selective phosphodiestherase inhibitors
WO2007075572A3 (en) Orally active purine-based inhibitors of heat shock protein 90
WO2008004165A3 (en) Use of c-glycoside derivatives as pro-desquamating active agents
KR20080070782A (en) Sugar intake promoters
WO1999012545A3 (en) Medicaments containing acyclovir
WO2003017932A3 (en) Compositions and methods for targeting cerebral circulation and treatment of headache
PA8519501A1 (en) FARNESIL TRANSFER INHIBITOR OF THE 1,2-RING QUINOLINE DUMPER
DE69800804D1 (en) SEMI-SOLID PHARMACEUTICAL PREPARATIONS CONTAINING DEXKETOPROFEN-TROMETAMOL

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NO NZ OM PH PT RO RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
B Later publication of amended claims

Free format text: 20030327

WWE Wipo information: entry into national phase

Ref document number: 10483509

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002753504

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002753504

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP